Willmann Stefan, Lippert Jörg, Schmitt Walter
Bayer Technology Services GmbH, Process Technology/Biophysics, 42096 Wuppertal, Germany.
Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):159-68. doi: 10.1517/17425255.1.1.159.
During the past decade, the pharmaceutical industry has invested considerably in technologies that have the potential to increase throughput in discovery projects. For large compound libraries, efficacy, availability and safety should be determined as early and as reliably as possible. The latest step in this effort is the implementation of in silico methods that combine and interpret (sometimes replace) experimental in vitro data. For ADME properties (absorption, distribution, metabolism and excretion) rational predictive models have been developed that rely on basic physicochemical input data and on mechanistic descriptions of the underlying biophysical and biochemical processes. Some of these models have become commercially available (e.g., GastroPlus: Simulations Plus; PK-Map, PK-Sim: Bayer Technology Services). The contribution of such models to an optimised research and development process will be discussed.
在过去十年中,制药行业在有可能提高发现项目通量的技术上投入了大量资金。对于大型化合物库,应尽早且尽可能可靠地确定其功效、可用性和安全性。这项工作的最新进展是实施了计算机模拟方法,该方法可结合并解释(有时替代)体外实验数据。针对药物的吸收、分布、代谢和排泄(ADME)特性,已经开发出了合理的预测模型,这些模型依赖于基本的物理化学输入数据以及对潜在生物物理和生化过程的机理描述。其中一些模型已经商业化(例如,GastroPlus:Simulations Plus公司;PK-Map、PK-Sim:拜耳技术服务公司)。将讨论此类模型对优化研发过程的贡献。